Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 48Recruiting 15Active not recruiting 14Terminated 9Unknown 7Withdrawn 3Not yet recruiting 1Approved for marketing 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Genitourinary 1

Conditions

Melanoma 17Carcinoma, Non-Small-Cell Lung 13Squamous Cell Carcinoma of Head and Neck 7Lung Neoplasms 5Colorectal Neoplasms 5Neoplasm Metastasis 4Head and Neck Neoplasms 4Neoplasms 3Multiple Myeloma 3Lymphoma 3Leukemia, Myeloid, Acute 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Sarcoma 2Myelodysplastic Syndromes 2Lymphoma, B-Cell 2Hematologic Neoplasms 2Esophageal Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Adenocarcinoma 2Xeroderma Pigmentosum 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uveal Melanoma 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Resectable Non-Small Cell Lung Cancer 1

Interventions

Cisplatin 9pembrolizumab 7Radiosurgery 6Gemcitabine 6Paclitaxel 5Dexamethasone 5Taxes 4Carboplatin 4trametinib 3ibrutinib 3Surveys and Questionnaires 3Standard of Care 3Radiotherapy 3Nivolumab 3Magnetic Resonance Spectroscopy 3Lenalidomide 3Fluorouracil 3Erlotinib Hydrochloride 3Blood Specimen Collection 3Ascorbic Acid 3venetoclax 2veliparib 2tocilizumab 2pazopanib 2obinutuzumab 2naquotinib 2lenvatinib 2fludarabine 2enzalutamide 2Vemurafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Neoplasms × Nivolumab × Clear all
NCT05898828 2024-08-05

Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
Gastrointestinal

Esophageal Neoplasms, Neoplasms

NCT05153304 2024-06-10

Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers

University of California, San Diego

Phase 1/2 Withdrawn
Gastrointestinal

Gastrointestinal Neoplasms, Neoplasms

NCT02962804 2018-03-05

Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)

University of Kansas Medical Center

Phase 2 Withdrawn
Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡